Autopsy report · NCT04434118

Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients

“Institutional Issue”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Sadat City University

Sponsor type

University, hospital or other

Conditions

Rheumatoid Arthritis; COVID

Interventions

Traditional antirheumatic drugs

Participants

0

Sites

1

Countries

Egypt

Trials that died the same way

• Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
  “Institutional and funding constrains” (70% match in meaning)
• TC02 Obese Women Using It Morphine vs PCA IV Hydromorphone for Post-Cesarean Analgesia
  “Change in institutional policy. Change in resources available.” (68% match in meaning)
• Point of Care Ultrasound in Obstetric Triage
  “Feasibility issue at institution” (58% match in meaning)
• Recurrent Urinary Tract Infections and the Microbiome
  “No longer with institution” (57% match in meaning)
• Prognostic Assessment of Different Pattern of Bifurcation Restenosis
  “Funding issues” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.